<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287728</url>
  </required_header>
  <id_info>
    <org_study_id>2010-022182-10</org_study_id>
    <secondary_id>2010 13</secondary_id>
    <nct_id>NCT01287728</nct_id>
  </id_info>
  <brief_title>The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy</brief_title>
  <official_title>The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abnormal vaginal flora is currently diagnosed among women (20-40%). It is associated with&#xD;
      symptoms (bad smell, vaginal discharge) and adverse out-comes in pregnant and not pregnant&#xD;
      women. The high recurrence rate raises the long-term effectiveness of therapy. The hypothesis&#xD;
      is the persistence of bacteria associated with vaginal flora imbalance as Atopobium vaginae&#xD;
      and Gardnerella vaginalis. At the present time there is a lack of an accurate marker for the&#xD;
      risk of recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with symptomatic abnormal vaginal flora (a Nugent score of 4-10 or sup or egal 3 Amsel&#xD;
      criteria) will be enrolled. Abnormal vaginal flora will be treated with 2g of oral&#xD;
      metronidazole. Follow-up will be performed at 1 week,1 month and 12 months after treatment.&#xD;
      Vaginal samples will be tested by quantitative real time PCR to determine the vaginal&#xD;
      concentrations of A. vaginae, G. vaginalis, and Lactobacillus spp.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To access the value of A. vaginae and G. vaginalis loads in predicting recurrence of abnormal vaginal flora over the course of 12 months after oral metronidazole therapy.</measure>
    <time_frame>2 YEARS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inform the predictive and technical characteristics (sensibility and specificity) vaginal microbial concentrations</measure>
    <time_frame>2 YEARS</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">182</enrollment>
  <condition>Abnormal Vaginal Flora</condition>
  <arm_group>
    <arm_group_label>treatment BY METROMIDAZOLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment BY METROMIDAZOLE</intervention_name>
    <description>Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole</description>
    <arm_group_label>treatment BY METROMIDAZOLE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Woman of more than 18 years, presenting vulvo-vaginal symptoms to type(chap) of smell&#xD;
             or abnormal vaginal losses the day of the inclusion and having an imbalance of the&#xD;
             vaginal flora objectivized by:&#xD;
&#xD;
          -  The presence of at least 3 clinical criteria of Amsel ( 41 ) is a score of Nugent &gt; 4&#xD;
             ( 42 )&#xD;
&#xD;
          -  Woman in genital encircled period of activity (negative pregnancy test in the&#xD;
             inclusion) and under effective contraception, including an intra-uterine device&#xD;
             (mechanical, hormonal).&#xD;
&#xD;
          -  Woman ménopausée with or without hormonal treatment (by way oral, transcutaneous, sous&#xD;
             cutaneous, vaginal).&#xD;
&#xD;
          -  Woman encircled at the time of the inclusion.&#xD;
&#xD;
          -  Having Woman was treated(handled) for a vaginal infection or one imbalance of the&#xD;
             vaginal flora more than 7 days ago.&#xD;
&#xD;
          -  Woman having understood(included) the progress and the objectives of the study and&#xD;
             having agreed to sign a lit(enlightened) consent.&#xD;
&#xD;
          -  Only the profitable women of a national insurance scheme will be included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Woman presenting a sexually transmitted infection (infection with gonococcus, with&#xD;
             Chlamydia trachomatis, with Trichomonas vaginalis) revealing on the takings realized&#xD;
             during the consultation of inclusion but the bacteriological results(profits) of which&#xD;
             will be known only secondarily.&#xD;
&#xD;
          -  Pregnant Woman presenting to the consultation of inclusion of métrorragies either a&#xD;
             break of the pocket of waters or an infectious complication of the pregnancy.&#xD;
&#xD;
          -  Woman removing her consent during the study.&#xD;
&#xD;
          -  Lost sight Woman.&#xD;
&#xD;
          -  Woman deprived of freedom, judicial or administrative;&#xD;
&#xD;
          -  Woman hospitalized for quite other reason that looks for her(it);&#xD;
&#xD;
          -  Woman hospitalized in a sanitary establishment or social in the other purposes that&#xD;
             the research;&#xD;
&#xD;
          -  Major Woman except state to express its consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique hôpitaux de Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <name_title>direction de la recherche</name_title>
    <organization>ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

